nivolumab-relatlimab
Formulary restricted to use by oncologist in the outpatient setting only for FDA approved indications. Insurance certification to be evaluated prior to initial dose. May use patient own supply through patient assistance program if eligible.
Reviewed: November 2023
Nivolumab/Relatlimab-rmbw (Opdualag)
Formulary restricted to use by oncologist in the outpatient setting only for FDA approved indications. Insurance certification to be evaluated prior to initial dose. May use patient own supply through patient assistance program if eligible.
Reviewed: November 2023
Nivolumab/Relatlimab-rmbw (Opdualag)